Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 189.55%4.5M | 129.04%1.49M | -52.39%391K | 5.73%3.61M | -47.96%581.67K | -1.86%1.55M | 120.58%650.66K | 97.51%821.22K | -44.21%3.41M | -41.04%1.12M |
| Selling and administrative expenses | 57.45%225.09K | 754.95%983.18K | -19.50%69.39K | 21.09%441.53K | 10.93%97.37K | 14.25%142.96K | 316.54%115K | -30.55%86.19K | -76.32%364.63K | -28.94%87.78K |
| -General and administrative expense | 57.45%225.09K | 754.95%983.18K | -19.50%69.39K | 21.09%441.53K | 10.93%97.37K | 14.25%142.96K | 316.54%115K | -30.55%86.19K | -76.32%364.63K | -28.94%87.78K |
| Other operating expenses | 202.94%4.27M | -5.33%507.1K | -56.24%321.62K | 3.90%3.17M | -52.98%484.3K | -3.24%1.41M | 100.34%535.66K | 152.00%735.03K | -33.41%3.05M | -41.89%1.03M |
| Operating profit | -189.55%-4.5M | -129.04%-1.49M | 52.39%-391K | -5.73%-3.61M | 47.96%-581.67K | 1.86%-1.55M | -120.58%-650.66K | -97.51%-821.22K | 44.21%-3.41M | 41.04%-1.12M |
| Net non-operating interest income (expenses) | ||||||||||
| Other net income (expenses) | 155.54%11.64K | -360.17%-8.66K | 352.86%16.47K | -482.96%-27.29K | -120.64%-3.15K | -677.51%-20.95K | 134.51%3.33K | -254.63%-6.51K | -74.23%7.13K | -78.95%15.26K |
| Gain on sale of security | -67.69%-16.26K | -3,179.36%-52.66K | 227.17%12.78K | -50.99%-21.8K | -159.72%-3.77K | 14.22%-9.7K | 120.92%1.71K | -689.24%-10.05K | -293.92%-14.44K | -89.78%6.31K |
| Other non-operating income (expenses) | 347.80%27.9K | 2,617.48%44K | 4.47%3.69K | -125.43%-5.48K | -93.06%621 | -230.79%-11.26K | 209.91%1.62K | -35.57%3.53K | 6.75%21.56K | -16.78%8.94K |
| Income before tax | -184.96%-4.49M | -131.56%-1.5M | 54.75%-374.53K | -6.76%-3.63M | 46.96%-584.82K | 0.70%-1.57M | -112.50%-647.33K | -101.12%-827.74K | 44.08%-3.4M | 39.54%-1.1M |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -184.96%-4.49M | -131.56%-1.5M | 54.75%-374.53K | -6.76%-3.63M | 46.96%-584.82K | 0.70%-1.57M | -112.50%-647.33K | -101.12%-827.74K | 44.08%-3.4M | 39.54%-1.1M |
| Net income continuous operations | -184.96%-4.49M | -131.56%-1.5M | 54.75%-374.53K | -6.76%-3.63M | 46.96%-584.82K | 0.70%-1.57M | -112.50%-647.33K | -101.12%-827.74K | 44.08%-3.4M | 39.54%-1.1M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -184.96%-4.49M | -131.56%-1.5M | 54.75%-374.53K | -6.76%-3.63M | 46.96%-584.82K | 0.70%-1.57M | -112.50%-647.33K | -101.12%-827.74K | 44.08%-3.4M | 39.54%-1.1M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -184.96%-4.49M | -131.56%-1.5M | 54.75%-374.53K | -6.76%-3.63M | 46.96%-584.82K | 0.70%-1.57M | -112.50%-647.33K | -101.12%-827.74K | 44.08%-3.4M | 39.54%-1.1M |
| Diluted earnings per share | -100.00%-0.04 | 0.00%-0.01 | 0 | 16.67%-0.05 | 0 | 33.33%-0.02 | 0.00%-0.01 | 0.00%-0.01 | 53.85%-0.06 | 50.00%-0.02 |
| Basic earnings per share | -100.00%-0.04 | 0.00%-0.01 | 0 | 16.67%-0.05 | 0 | 33.33%-0.02 | 0.00%-0.01 | 0.00%-0.01 | 53.85%-0.06 | 50.00%-0.02 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.